Welcome to our dedicated page for Adaptimmune Therapeutics Plc SEC filings (Ticker: ADAP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Adaptimmune Therapeutics plc (ADAP) SEC filings page on Stock Titan provides structured access to the company’s regulatory disclosures as an issuer with American Depositary Shares previously listed on The Nasdaq Capital Market. These filings include current reports on Form 8-K, annual and quarterly reports referenced in company communications, and other documents that outline Adaptimmune’s financial condition, strategic transactions and corporate governance developments.
Through its Form 8-K filings, Adaptimmune reports material events such as notices from Nasdaq regarding minimum bid price deficiencies and the Low Priced Stocks Rule, approval to transfer its listing to the Nasdaq Capital Market, and the Board’s decision to voluntarily delist its ADSs and deregister them under Section 12(b) of the Securities Exchange Act of 1934. Filings also describe the company’s intention to file a Form 25 to effect the delisting and a subsequent Form 15 to suspend its reporting obligations once eligibility criteria are met.
Other key SEC documents detail the Asset Purchase Agreement and related transaction by which Adaptimmune sold the assets and rights related to its TECELRA, lete-cel, afami-cel and uza-cel cell therapies to USWM CT, LLC, a subsidiary of US WorldMeds Partners, LLC. These filings outline the upfront cash consideration, potential milestone payments, assumed liabilities, and associated license and transition services agreements, as well as the use of proceeds to repay indebtedness under a Loan and Security Agreement with Hercules Capital, Inc.
Adaptimmune’s 8-K filings also cover restructuring actions and workforce reductions, executive leadership changes, and separation or consulting agreements with senior officers, providing detail on severance terms and responsibilities. Financial information referenced in these filings, including revenue, research and development expenses, selling, general and administrative expenses, net income or loss, and the non-GAAP Total Liquidity measure, can be compared with press release summaries for a fuller picture of the company’s performance.
Stock Titan enhances these SEC filings with AI-powered summaries that highlight the most important points from lengthy documents, helping readers quickly understand listing status changes, asset sales, restructuring plans and liquidity disclosures. Real-time updates from EDGAR ensure that new 8-Ks and other filings appear promptly, while structured views make it easier to follow Adaptimmune’s transition from a Nasdaq-listed cell therapy company with commercial assets to an issuer focused on remaining preclinical programs and strategic alternatives.
Adaptimmune Therapeutics plc filed a Rule 424(b)(3) prospectus for its Form F‑6 American Depositary Share program. The ADR outlines terms under which Citibank, N.A., as depositary, issues ADSs, with each ADS representing the right to receive six ordinary shares of Adaptimmune deposited with Citibank, N.A. London Branch.
The document details core mechanics: surrender and withdrawal of shares, transfers and split-ups, fees and taxes, distributions (cash, shares, rights), voting procedures, record dates, and changes affecting deposited securities. It also describes circumstances for suspending deposits or transfers and sets liability standards for the depositary and the company.
The company has filed a Form 15 to terminate Exchange Act registration; reporting duties were suspended upon filing and will terminate upon effectiveness. Adaptimmune states it intends to continue publishing an IFRS annual report on its website.
Christopher James Hill, identified as Chief Financial Officer and a director of Adaptimmune Therapeutics PLC (ADAP), filed an Initial Form 3 reporting that he does not beneficially own any securities of the issuer as of the event date 09/10/2025. The filing is signed 10/08/2025 and lists the reporter's business address in Abingdon, UK. No non-derivative or derivative holdings are disclosed on the form.
Adaptimmune Therapeutics plc received a written notice from a Nasdaq Hearings Panel on September 22, 2025 granting extra time to fix its share price listing issue. The Panel gave the company until December 1, 2025 to regain compliance with Nasdaq’s minimum bid price requirement of $1.00 per share under Listing Rule 5550(a)(2), often called the Bid Price Rule.
If Adaptimmune does not meet this minimum bid price by December 1, 2025, its American Depositary Shares will be delisted from The Nasdaq Capital Market, which could reduce trading liquidity and market visibility for shareholders.
Adaptimmune Therapeutics plc has appointed Christopher Hill as its Chief Financial Officer through a consulting arrangement. Adaptimmune Limited, a subsidiary, entered into a consulting agreement with CJH Financial Limited on September 6, 2025, under which Mr. Hill will serve as CFO effective September 10, 2025.
Mr. Hill will oversee the company’s accounting and finance functions and act as the main contact with its independent auditors for quarterly and annual SEC reports. He will serve as an independent contractor, with CJH Financial Limited paid £2,200 (approximately $2,968) per day based on approved timesheets, and he will not be eligible for bonuses or share options.
The consulting agreement can be terminated by either party after a material breach, with 30 days’ notice if curable or immediately if not curable. Mr. Hill, age 45, brings over a decade of CFO and COO experience in public and private life science and therapeutics companies, and there are no disclosed related-party transactions or family relationships tied to his appointment.
Adaptimmune insider sale by CFO Gavin Wood: The Form 4 shows that Gavin Wood, Chief Financial Officer and director of Adaptimmune Therapeutics plc (ADAP), sold the equivalent of 96,000 ordinary shares on 09/02/2025. Those shares were represented by 16,000 ADSs, each ADS equal to six ordinary shares, and were sold at $0.0594 per ADS (reported as $0.0099 per ordinary share). After this transaction the reporting person holds 0 ADSs but retains nominal cost and other options covering 11,140,760 ordinary shares of the issuer.
Form 144 notice for Adaptimmune Therapeutics plc (ADAP) reports a proposed sale of 16,000 American Depositary Shares (ADS) with an aggregate market value of $942.40, to be sold on or about 09/02/2025 on Nasdaq. The filing shows the ADS were acquired in three open-market purchases: 5,500 on 06/29/2020, 4,000 on 12/14/2020, and 6,500 on 05/20/2022, all paid in cash. The filing states there were no securities sold in the past three months by the selling person. Several identifying fields for the filer and issuer (names, CIK) are blank in the provided content.
Adaptimmune Therapeutics plc reporting person William C. Bertrand, Jr., who is Chief Operating Officer and a director, disclosed the sale of 207,000 ordinary shares (represented by 34,500 ADSs) on 08/28/2025 at an ADS sale price of $0.0603 (equivalent to $0.01005 per ordinary share). After the reported sale he beneficially owns 986,352 ordinary shares (164,392 ADSs). The filing states he also holds RSU-style options and other options covering an aggregate of 16,108,722 ordinary shares. The Form 4 is signed 08/29/2025 and indicates the securities sold were ADSs representing ordinary shares.
Adaptimmune Therapeutics plc (ADAP) Form 144 notice reports a proposed sale of 34,500 American Depositary Shares (ADS) executed through ETrade by Morgan Stanley with an approximate sale date of 08/28/2025 on Nasdaq. The filing shows an aggregate market value of $2,070 for the shares and lists 256,032,610 shares outstanding. The securities were acquired in an open-market purchase on 12/14/2020 for cash by the person filing, and no securities were reported sold in the prior three months. Several filer and issuer identification fields in the document are left blank in the provided content.
Adaptimmune Therapeutics plc disclosed a Second Variation Letter Agreement affecting the share options of Mr. Wood. Under the revised terms, registered awards will continue to vest until a Revised Termination Date in line with the Plan rules and their original vesting schedules. Mr. Wood is allowed a 12‑month period from that Revised Termination Date to exercise any Market Value Options that have vested by then. The filing states that the summary is qualified by the full agreement filed as Exhibit 10.1 to the Current Report.
FAQ
What is the current stock price of Adaptimmune Therapeutics Plc (ADAP)?
What is the market cap of Adaptimmune Therapeutics Plc (ADAP)?
